Divi's Laboratories schedules Q1 FY27 earnings call for August 1
Divi's Laboratories Limited scheduled an earnings call for August 01, 2026, at 14:00 IST to review Q1 FY27 results. The unaudited financials for the quarter ended June 30, 2026, will be released prior to the call. Investors can join via dial-in or DiamondPass registration.

*this image is generated using AI for illustrative purposes only.
Divi's Laboratories Limited will host an earnings conference call on August 01, 2026, at 14:00 IST to discuss its financial performance for the quarter ended June 30, 2026 (Q1 FY27). The company announced that it will release its unaudited financial results for the period on the same day, preceding the investor discussion. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Earnings Call Details
The management team will be available to address queries from investors and analysts regarding the Q1 FY27 results. A transcript of the conference call will be made available on the company’s website, www.divislabs.com , after the event concludes. Investors are advised to join the call approximately five minutes before the scheduled start time to receive instructions from the operator.
Dial-In Information
Participants can access the call via two methods: Express Join with DiamondPass™ or through standard dial-in numbers. Pre-registration for DiamondPass allows participants to join without waiting for an operator.
| Access Method | Details |
|---|---|
| DiamondPass Registration | Click here to register |
| Universal Dial-In | +91 22 6280 1526 +91 22 7115 8341 |
Contact Information
For further inquiries, investors may contact the Investor Relations department:
- Mobile: +91 91542 18881
- Phone: +91 40 66966352
- Email: mail@divislabs.com
The registered office of Divi's Laboratories Limited is located at Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India.
Historical Stock Returns for Divis Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.02% | -1.58% | +6.72% | +19.78% | +8.23% | +49.24% |
How might Divi's Laboratories' Q1 FY27 margin performance signal the broader trend of pricing pressure in the global API and generic drug markets?
What impact could the company's capital expenditure plans discussed in the call have on its future capacity expansion and market share in key therapeutic segments?
Will regulatory updates from major markets like the US FDA or EMA significantly influence Divi's Laboratories' export volumes and revenue mix for the remainder of FY27?


































